

1 **Estimation of SARS-CoV-2 aerosol emissions from simulated**
2 **patients with COVID-19 and no to moderate symptoms**

3 A.A.Prof. Dr. Michael Riediker¹, Dr. Dai-Hua Tsai^{1,2}

4 1 Swiss Centre for Occupational and Environmental Health, Winterthur, Switzerland

5 2 Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of

6 Psychiatry Zurich, University of Zurich, Zurich, Switzerland

7 **Date of revision:** 2 June 2020

8 **Word counts:** Abstract: 302, Manuscript: 2398, Tables: 1, Figures: 3

9 [Address for correspondence](#)

10 Michael Riediker

11 michael.riediker@alumni.ethz.ch

12 +41 77 431 08 58

13 Swiss Centre for Occupational and Environmental Health (SCOEH)

14 Binzhofstrasse 87

15 CH-8404 Winterthur

16 Switzerland

17

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

18 Key Points

19 **Question:** How much SARS-CoV-2 virus is released from a case by breathing and coughing,
20 and what is the resulting concentration in a room?

21 **Finding:** In this mathematical modelling study, both, breathing and coughing were estimated
22 to release large numbers of viruses, which can lead to billions of virus copies/m³ in a poorly
23 ventilated room with a coughing emitter.

24 **Meaning:** These results may explain the important rate of transmissions and implies the
25 need for strict respiratory protection when people are in the same room with a case with
26 COVID-19.

27 Abstract

28 **Importance:** Cases of the coronavirus disease 2019 (COVID-19) with no or mild symptoms
29 were reported to frequently transmit the disease even without direct contact. The severe
30 acute respiratory syndrome virus (SARS-COV-2) was found at very high concentrations in
31 swab and sputum of such cases.

32 **Objective:** We aimed to estimate in a mathematical modeling study the virus release from
33 such cases into different aerosol sizes by normal breathing and coughing, and what exposure
34 can result from this in a room shared with such as case.

35 **Data Sources and Model:** We combined the size-distribution of exhaled breath
36 microdroplets for coughing and normal breathing with viral sputum concentrations as
37 approximation for lung lining liquid to obtain an estimate of emitted virus levels. The
38 resulting emission data fed a single-compartment model of airborne concentrations in a
39 room of 50 m³, the size of a small office or medical exam room.

40 **Results:** The estimated viral load in microdroplets emitted by simulated patients while
41 breathing normally was on average 0.0049 copies/cm³ and could go up to 24.5 copies/cm³.
42 The corresponding numbers for coughing simulated patients were 277 copies/cm³ and
43 1,385,777 /cm³, respectively, per cough. The resulting concentrations in a room with a
44 coughing emitter were always very high, up to 286 million copies/m³. However, also regular
45 breathing microdroplets from high emitters was modelled to lead to several thousand
46 copies/m³.

47 **Conclusions and Relevance:** In this modelling study, breathing and coughing were estimated
48 to release large numbers of viruses, ranging from thousands to billions of virus copies/m³ in
49 a room with an emitter having a high viral load, depending on ventilation and microdroplet
50 formation process. These findings suggest that strict respiratory protection may be needed
51 when there is a chance to be in the same room with a patient - whether symptomatic or not
52 - especially for a prolonged time.

53 Introduction

54 The novel Coronavirus disease 2019 (COVID-19), emerged in late 2019 in Wuhan, China ¹
55 from where it spread to the entire world. COVID-19 is caused by a novel type of Coronavirus,
56 the severe acute respiratory syndrome virus (SARS-COV-2) ². The host-receptor for SARS-
57 CoV-2 was found to be Angiotensin I converting enzyme 2 (ACE2), which is present in cells of
58 the lungs and airways ³. In the early phase of the outbreak, a large number of patients
59 hospitalized for other reasons ⁴ and a considerable proportion of the medical staff ⁵
60 contracted COVID-19. However, the attack rate among medical staff corresponded to
61 community rates when respiratory personal protective equipment (PPE) was used at work
62 ^{6,7}. Also a series of community-transmissions were reported from cases that had no apparent
63 symptoms ⁸⁻¹¹. The estimates for community and household attack rates are currently in the

64 range of 1 % and 10 %, respectively ¹²⁻¹⁵. However, during super-spreading events in
65 situations where many people engaged in loud voice activities gathered in closed rooms for
66 prolonged time, such as a restaurant ¹⁶, a call-center ¹⁷, a dermatologists scientific board
67 meeting ¹⁸, and a choir rehearsal ¹⁹ attack rates above 75% were reported. Notably, the choir
68 rehearsal participants tried to follow social distancing and hand washing rules. These super-
69 spreading events suggest that the airborne route may represent a virus transmission form in
70 some indoor situations. Indeed, a study conducted in a Wuhan hospital found low airborne
71 concentrations of the virus in the intensive care unit and in medical staff rooms ²⁰.
72 Correspondences about the viral load in samples from patients with COVID-19 having no or
73 only mild symptoms reported very high concentrations of SARS-CoV-2 in samples taken in
74 the nose, throat and saliva ^{11,21-23}, and high during antiviral treatment ²⁴. This all raised the
75 question whether transfections could occur via the air.

76 When coughing, humans release thousands of microdroplets per cubic-centimeter in the size
77 range of 0.6 to 15 μm , with the droplet concentration increasing strongly with cough flow
78 rate ²⁵. But also normal breathing will lead to some microdroplet production, which is
79 attributed to fluid film rupture in the respiratory bronchioles during inhalation leading to the
80 formation of droplets that are released during exhalation ²⁶. The size of these droplets is
81 mostly below 1 μm ²⁷. The mode of droplet generation implies that they consist of lung lining
82 liquid including dispersed viruses. Indeed, human volunteers exposed to virus-sized
83 nanoparticles show nano-scaled particles in their exhaled breath ^{28,29}. Also, the described
84 size distribution of particles emitted from coughing as well as normal respiration suggests
85 that an important proportion of them will be able to remain airborne for many hours in
86 turbulent conditions ³⁰.

87 Objectives

88 This study aimed to estimate the cumulative viral load released from simulated patients with
89 COVID-19 with no to moderate symptoms in different microdroplet sizes via respiration and
90 coughing. We then used this information to make a risk appraisal for the situation of a low,
91 average or high emitter that is either breathing normally or coughing in a room operated at
92 different air exchange rates. We chose a room size that is similar to a medical examination
93 room or an office shared by two to three people.

94 Design and Methods

95 Concept:

96 The release of viruses from individual simulated patients was modeled by first calculating
97 the viral load per exhaled microdroplets formed during normal breathing and while
98 coughing. The resulting size-distribution provided an initial estimate of the concentration of
99 SARS-CoV-2 virus copies released by a regularly breathing or coughing simulated patient.
100 This viral emission factor was then fed into a well-mixed one-compartment model to
101 simulate the situation in a closed room with different ventilation air exchange rates. This
102 study follows the concept of Strengthening The Reporting of Empirical Simulation Studies
103 (STRESS) guideline³¹. This mathematical modelling corresponds to a meta-analysis and was
104 as such exempt from ethics approval.

105 Data sources:

106 Data on the number of viral copies present in sputum and swab samples were used to
107 estimate the SARS-CoV-2 viral load present in the lining liquid of respiratory bronchioles in
108 patients published before the here presented modelling (May 2020)^{11,21-24,32}, specifically
109 1,000 copies/ml representing a low-virus producing patient ("low emitter"), an "average
110 emitter" producing 10^6 copies/ml, and a "high emitter" producing $5 \cdot 10^9$ copies/ml.

111 Exhaled microdroplet size distributions and numbers were retrieved from published studies
112 on healthy persons coughing²⁵ and breathing normally²⁶. Both studies assessed the size-
113 number distribution of freshly emitted microdroplets. The concentration of viral copies in
114 each microdroplet size was calculated from the volume of the microdroplets, the actual
115 count number in each size and the above-mentioned virus-load per ml sputum. The viral
116 load in the actual microdroplet counts in each microdroplet size was then used to calculate
117 the total viral concentration. The cumulative emissions in the PM₁₀ fraction were summed
118 up after applying the standard size fractionation curves³³ to the microdroplet distribution.

119 Model:

120 A one-compartment model³⁴ estimated the virus load concentration C for a perfectly mixed
121 room of volume V_R of 50 m³ with one simulated patient as source, using the following mass-
122 balance (equation 1):

$$123 \quad V_R * \frac{dC}{dt} = c_{PM10} * RR * V_t - V_R * ER * C(t) - \frac{\ln(2)*V_R}{t_{1/2}} * C(t) \quad (1)$$

124 The emission rate was calculated from the concentration c_{PM10} , the viral load in the PM₁₀-
125 size range, which are particles collected with a 50% efficiency cut-off at 10 µm aerodynamic
126 diameter; and a respiratory rate of 15 breaths per minute (RR) at a tidal volume of V_t of 500
127 ml per breath. Air exchange rates (ER) used were 1-, 3-, 10- and 20-times per hour. The virus'
128 half-life $t_{1/2}$ of 1.1 hours was obtained from an experimental study about the persistence of
129 SARS-CoV-2 on surfaces and when airborne³⁵, tested by assessing the 50% tissue culture
130 infective dose (TCID₅₀).

131 The model for coughing was identical, except that coughing was assumed to happen every
132 30 seconds at a volume of 250 ml, as described for chronic dry cough patient (not having
133 COVID-19)³⁶.

134 All statistics and models were calculated using Stata/SE 15.1 (Mac 64-bit Intel, Rev. 03 Feb
135 2020, StataCorp, College Station, TX, USA). Robust data reported include estimated averages
136 and ranges. The models and code are available on request.

137 Results

138 Emissions from normal breathing simulated patients

139 To estimate the virus emissions from simulated patients breathing normally, we first
140 calculated the viral load for the microdroplet size distribution. Figure 1 shows that the
141 highest virus load is present in the largest microdroplet size. The cumulative total emission
142 per breath was 0.0000049 copies/cm³(air) for a low emitter, 0.0049 copies/cm³ for an
143 average simulated patient, and 24.5 copies/cm³ for a high emitter. The cumulative emissions
144 in the PM₁₀ fraction were approximately 1/3 of these values with 0.0017 copies/cm³
145 (average) and 8.69copies/cm³ (high) per breath.

146 Emission from coughing simulated patient

147 We then estimated the virus emissions from a coughing simulated patient (Figure 2). The
148 cumulative total emission per cough was 0.277 copies/cm³ for a low emitter, 277 copies/cm³
149 for an average simulated patient, and 1,385,777 copies/cm³ for a high emitter. The
150 cumulative emissions in the PM₁₀ fraction were about 1/2 of these values with 10,900
151 copies/cm³ (average) and 366,000 copies/cm³ (high) per cough.

152 Exposure estimation for bystanders

153 To estimate the exposure of bystanders spending time in the same room as a person with
154 COVID-19, we calculated the time-course of the viral load in the thoracic size fraction for
155 small droplets released from a high-emitter either breathing normally or coughing. Figure 3
156 shows the results for a high-emitting simulated patient coughing frequently.

157 For a typical hospital ventilation situation of 10 air exchanges per hour, the concentration
158 plateaus after about 30 minutes, while for a typical office with 3 air exchanges/hour,
159 concentrations continue to rise for over one hours. In the used model, concentrations scale
160 linearly with the simulated patient emission rate, the plateau concentrations for different
161 emitting simulated patients and ventilation types are summarized in Table 1.

162 Discussion

163 An elevated number of viruses is expected to be released by patients with COVID-19 having
164 high viral load in the form of airborne microdroplets, especially when they are coughing.
165 While the bigger portion of the emitted viral load is in the form of large droplets that can
166 deposit rapidly, there is also an important portion in the smaller size fractions. Small
167 microdroplets can remain airborne for an extended time ³⁰ and are very effective at reaching
168 the lungs ³⁷.

169 One study assessed airborne SARS-CoV-2 levels in a hospital in Wuhan, China and found
170 concentrations in the range of 20 copies/m³ in medical staff offices and meeting rooms ²⁰,
171 concentrations that our modelling would suggest for a small room with a regularly breathing
172 non-symptomatic person having a viral load slightly above an average emitter.

173 An average person breathes about a half m³ per hour in resting state ³⁸, which can rapidly
174 increase to several m³ during exercise ³⁹. Thus, a person spending time in a room with an
175 average emitting patient breathing normally has the chance of inhaling only a few copies of
176 the virus when keeping distance from that person. However, the situation is worse in the
177 presence of a high emitter and worst if the patient is a coughing high emitter. A review of a
178 wide range of respiratory viruses suggests that the infective dose is often quite low.

179 Sometimes as few as few hundred units of active virus (TCID₅₀) ⁴⁰ seem sufficient to provoke
180 a disease. Thus, our modelling suggests that there is a clear risk of infections for a person

181 spending an extended time in the room with an infected person having an elevated viral
182 load, even if the distance is too large for direct transmission. The situation is worse if the
183 person is coughing.

184 High emitters are not very frequent in the population. However, if such a person is engaged
185 in activities such as loud speaking or singing, microdroplet formation and thus viral
186 emissions can rapidly increase by one to two orders of magnitude ⁴¹. This may help explain
187 the occasional superspreading events in crowded situations involving loud voices ¹⁶⁻¹⁹.

188 The occasionally very high virus load in exhaled respiratory microdroplets proposed by our
189 assessment may be an explanation why COVID-19 was associated with more transfusions to
190 hospital staff than what was expected from SARS ⁴. While having everybody wear a surgical
191 face mask can be an effective source control ⁴², the protective factors may still be
192 insufficient if an extended amount of time is spent in the same room with a coughing high
193 emitter, especially if the room is small and the ventilation low. Increasing ventilation can
194 help to some extent but is not sufficient in a room of the size of a typical office or medical
195 exam room. Note also that ventilation design for hospitals is complex and not always
196 functioning as intended ⁴³.

197 The implications for the normal life and the workplace are that the risk of infection is real
198 when being near an infected person with high viral load in a room for more than a few
199 minutes and this even when keeping distance to that person. Sharing a workplace in a small
200 room with a non-symptomatic case seems not advised. This implies that workplaces should
201 not be shared as long as there are no rapid tests to differentiate between healthy and non-
202 symptomatic cases. Medical staff is advised to wear the best possible respiratory protection
203 whenever in the same room as a patient, especially when this person is coughing, in which
204 case eye protection is advised as well ⁴⁴. In addition, every patient, also non-symptomatic

205 ones, should wear a well-fitting surgical face mask to reduce emissions, which will increase
206 the overall protection for the medical staff ⁴².

207 Limitations

208 Our assessment has a number of limitations. Namely: 1) The estimated virus levels strongly
209 depend on the number of virus copies produced by a case with COVID-19. We used sputum
210 data from a well described peer-reviewed study ²¹ assuming that it is a reasonable
211 approximation for the virus load in the respiratory bronchioles, the space where most
212 respiratory microdroplets are formed. Our high-emitter estimates would be 100-fold higher
213 if the most extreme correspondence data was used ²². 2) We used information about virus
214 copies but compare the results with TCID₅₀ infective dose. Research on other virus types
215 suggests that the number of virus copies and TCID₅₀ are comparable ⁴⁵. However, it would be
216 important to confirm this relationship for the case of SARS-CoV-2. 3) For breath and cough
217 microdroplets release, we used data collected in experimental setups involving healthy
218 young subjects. However, microdroplet formation is influenced by surface tension of the
219 lung lining liquid ⁴⁶. It is likely that microdroplet formation will be altered in cases with
220 COVID-19 but it is not clear in which direction. 4) Microdroplets will shrink in dry air ⁴⁷,
221 resulting in a shift to smaller particle sizes. This will not directly change the number of copies
222 in the PM₁₀ range but simply upconcentrate the viral load per microdroplet. While we
223 addressed passivation of viruses in the air by using the documented half-life ³⁵, it is still
224 possible that viruses in smaller droplets are quicker passivated because of shorter diffusion
225 distances for airborne oxidants and faster increasing salinity. Our estimates would be slightly
226 smaller if this was relevant. 5) The one-compartment model assumes perfectly mixed
227 conditions. However, often, rooms are not perfectly mixed and also ventilation and room
228 geometry will add spatiotemporal variability. The modelling provides an average estimate,
229 but exact concentrations will vary in function of the real circumstances. In multi-room

230 situations, numerical flow simulations seem indicated to describe the microdroplet
231 distribution ⁴⁸. 6) Finally, though our results suggest that in certain situations, airborne
232 transmission of COVID-19 may be possible, it is important to keep in mind that this was a
233 modelling effort. While this route would provide a convenient explanation for several
234 superspreading events ¹⁶⁻¹⁹, and even though the virus was found in airborne microdroplets
235 in hospital situations ²⁰, it still needs to be validated in clinical settings and animal models.

236 Conclusions

237 In conclusion, our mathematical modelling suggests that the viral load in the air can rapidly
238 reach critical concentrations in small and ill-ventilated rooms, especially when the patient is
239 a super-spreader defined as a person emitting large number of microdroplets containing a
240 high viral load. Thus, strict respiratory protection is needed whenever there is a chance to be
241 in the same room with such a patient - whether symptomatic or not - especially if this was
242 for a prolonged time.

243 Acknowledgments

244 This modelling was entirely funded by the Swiss Centre for Occupational and Environmental
245 Health (SCOEH). No external funder had any role in the design and conduct of the study;
246 collection, management, analysis, and interpretation of the data; preparation, review, or
247 approval of the manuscript; and decision to submit the manuscript for publication. Both
248 authors had full access to all the data in the study and take responsibility for the integrity of
249 the data and the accuracy of the data analysis.

250 References

251 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia
252 in China, 2019. *N Engl J Med*. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017

- 253 2. Gorbalenya AE, Baker SC, Baric RS, et al. *Severe Acute Respiratory Syndrome-*
254 *Related Coronavirus: The Species and Its Viruses – a Statement of the Coronavirus Study*
255 *Group*. Microbiology; 2020. doi:10.1101/2020.02.07.937862
- 256 3. Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues
257 identify cell types and receptors of human coronaviruses. *Biochem Biophys Res Commun*.
258 Published online March 2020:S0006291X20305234. doi:10.1016/j.bbrc.2020.03.044
- 259 4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With
260 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061.
261 doi:10.1001/jama.2020.1585
- 262 5. Chu J, Yang N, Wei Y, et al. Clinical characteristics of 54 medical staff with COVID-
263 19: A retrospective study in a single center in Wuhan, China. *J Med Virol*. Published online
264 April 6, 2020;jmv.25793. doi:10.1002/jmv.25793
- 265 6. Kluytmans-van den Bergh MFQ, Buiting AGM, Pas SD, et al. Prevalence and Clinical
266 Presentation of Health Care Workers With Symptoms of Coronavirus Disease 2019 in 2
267 Dutch Hospitals During an Early Phase of the Pandemic. *JAMA Netw Open*.
268 2020;3(5):e209673. doi:10.1001/jamanetworkopen.2020.9673
- 269 7. Cheng VC-C, Wong S-C, Yuen K-Y. Estimating Coronavirus Disease 2019 Infection
270 Risk in Health Care Workers. *JAMA Netw Open*. 2020;3(5):e209687.
271 doi:10.1001/jamanetworkopen.2020.9687
- 272 8. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-
273 19. *JAMA*. Published online February 21, 2020. doi:10.1001/jama.2020.2565
- 274 9. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and Presymptomatic SARS-
275 CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County,
276 Washington, March 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(13):377-381.
277 doi:10.15585/mmwr.mm6913e1

- 278 10. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid
279 dissemination of novel coronavirus (SARS-CoV2). *Science*. Published online March 16,
280 2020. doi:10.1126/science.abb3221
- 281 11. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory
282 Specimens of Infected Patients. *N Engl J Med*. 2020;382(12):1177-1179.
283 doi:10.1056/NEJMc2001737
- 284 12. Cheng H-Y, Jian S-W, Liu D-P, et al. Contact Tracing Assessment of COVID-19
285 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After
286 Symptom Onset. *JAMA Intern Med*. Published online May 1, 2020.
287 doi:10.1001/jamainternmed.2020.2020
- 288 13. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases
289 and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet*
290 *Infect Dis*. Published online April 2020:S1473309920302875. doi:10.1016/S1473-
291 3099(20)30287-5
- 292 14. Li W, Zhang B, Lu J, et al. The characteristics of household transmission of COVID-
293 19. *Clin Infect Dis*. Published online April 17, 2020:ciaa450. doi:10.1093/cid/ciaa450
- 294 15. COVID-19 National Emergency Response Center, Epidemiology and Case
295 Management Team, Korea Centers for Disease Control and Prevention. Coronavirus Disease-
296 19: Summary of 2,370 Contact Investigations of the First 30 Cases in the Republic of Korea.
297 *Osong Public Health Res Perspect*. 2020;11(2):81-84. doi:10.24171/j.phrp.2020.11.2.04
- 298 16. Lu J, Gu J, Li K, et al. COVID-19 Outbreak Associated with Air Conditioning in
299 Restaurant, Guangzhou, China, 2020. *Emerg Infect Dis*. 2020;26(7).
300 doi:10.3201/eid2607.200764
- 301 17. Shin Young Park, Young-Man Kim, Seonju Yi, et al. Coronavirus Disease Outbreak
302 in Call Center, South Korea. *Emerg Infect Dis J*. 2020;26(8). doi:10.3201/eid2608.201274

- 303 18. Hijnen D, Marzano AV, Eyerich K, et al. SARS-CoV-2 Transmission from
304 Presymptomatic Meeting Attendee, Germany. *Emerg Infect Dis.* 2020;26(8).
305 doi:10.3201/eid2608.201235
- 306 19. Hamner L, Dubbel P, Capron I, et al. High SARS-CoV-2 Attack Rate Following
307 Exposure at a Choir Practice — Skagit County, Washington, March 2020. *MMWR Morb*
308 *Mortal Wkly Rep.* 2020;69(19):606-610. doi:10.15585/mmwr.mm6919e6
- 309 20. Liu Y, Ning Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan
310 hospitals. *Nature.* Published online April 27, 2020. doi:10.1038/s41586-020-2271-3
- 311 21. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized
312 patients with COVID-2019. *Nature.* Published online April 1, 2020. doi:10.1038/s41586-020-
313 2196-x
- 314 22. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical
315 samples. *Lancet Infect Dis.* 2020;20(4):411-412. doi:10.1016/S1473-3099(20)30113-4
- 316 23. Pasomsub E, Watcharananan SP, Boonyawat K, et al. Saliva sample as a non-invasive
317 specimen for the diagnosis of coronavirus disease-2019 (COVID-19): a cross-sectional study.
318 *Clin Microbiol Infect.* Published online May 2020:S1198743X20302780.
319 doi:10.1016/j.cmi.2020.05.001
- 320 24. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients
321 infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective
322 cohort study. *BMJ.* Published online April 21, 2020:m1443. doi:10.1136/bmj.m1443
- 323 25. Yang S, Lee GWM, Chen C-M, Wu C-C, Yu K-P. The Size and Concentration of
324 Droplets Generated by Coughing in Human Subjects. *J Aerosol Med.* 2007;20(4):484-494.
325 doi:10.1089/jam.2007.0610
- 326 26. Johnson GR, Morawska L. The Mechanism of Breath Aerosol Formation. *J Aerosol*

- 327 *Med Pulm Drug Deliv.* 2009;22(3):229-237. doi:10.1089/jamp.2008.0720
- 328 27. Papineni RS, Rosenthal FS. The Size Distribution of Droplets in the Exhaled Breath of
329 Healthy Human Subjects. *J Aerosol Med.* 1997;10(2):105-116. doi:10.1089/jam.1997.10.105
- 330 28. Gschwind S, Graczyk H, Günther D, Riediker M. A method for the preservation and
331 determination of welding fume nanoparticles in exhaled breath condensate. *Env Sci Nano.*
332 2016;3(2):357–364. doi:10.1039/C5EN00240K
- 333 29. Sauvain J-J, Hohl MSS, Wild P, Pralong JA, Riediker M. Exhaled breath condensate
334 as a matrix for combustion-based nanoparticle exposure and health effect evaluation. *J*
335 *Aerosol Med Pulm Drug Deliv.* 2014;27(6):449–458. doi:10.1089/jamp.2013.1101
- 336 30. Willeke K, Baron PA, eds. *Aerosol Measurement: Principles, Techniques, and*
337 *Applications.* Van Nostrand Reinhold; 1993.
- 338 31. Monks T, Currie CSM, Onggo BS, Robinson S, Kunc M, Taylor SJE. Strengthening
339 the reporting of empirical simulation studies: Introducing the STRESS guidelines. *J Simul.*
340 2019;13(1):55-67. doi:10.1080/17477778.2018.1442155
- 341 32. The COVID-19 Investigation Team. Clinical and virologic characteristics of the first
342 12 patients with coronavirus disease 2019 (COVID-19) in the United States. *Nat Med.*
343 Published online April 23, 2020. doi:10.1038/s41591-020-0877-5
- 344 33. BSI. *EN 481:1993 Workplace Atmospheres. Size Fraction Definitions for*
345 *Measurement of Airborne Particles.* BSI; 1993.
- 346 34. Scheff PA, Paulius VK, Curtis L, Conroy LM. Indoor Air Quality in a Middle School,
347 Part II: Development of Emission Factors for Particulate Matter and Bioaerosols. *Appl Occup*
348 *Environ Hyg.* 2000;15(11):835-842. doi:10.1080/10473220050175715
- 349 35. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of
350 SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med.* Published online March 17,

- 351 2020:NEJMc2004973. doi:10.1056/NEJMc2004973
- 352 36. Hsu JY, Stone RA, Logan-Sinclair RB, Worsdell M, Busst CM, Chung KF. Coughing
353 frequency in patients with persistent cough: assessment using a 24 hour ambulatory recorder.
354 *Eur Respir J*. 1994;7(7):1246-1253. doi:10.1183/09031936.94.07071246
- 355 37. Lippmann M, Yeates DB, Albert RE. Deposition, retention, and clearance of inhaled
356 particles. *Br J Ind Med*. 1980;37(4):337-62.
- 357 38. Beardsell I, ed. *Get through MCEM. Part A: MCQs*. RSM; 2011.
- 358 39. Ramos CA, Reis JF, Almeida T, Alves F, Wolterbeek HT, Almeida SM. Estimating
359 the inhaled dose of pollutants during indoor physical activity. *Sci Total Environ*. 2015;527-
360 528:111-118. doi:10.1016/j.scitotenv.2015.04.120
- 361 40. Yezli S, Otter JA. Minimum Infective Dose of the Major Human Respiratory and
362 Enteric Viruses Transmitted Through Food and the Environment. *Food Environ Virol*.
363 2011;3(1):1-30. doi:10.1007/s12560-011-9056-7
- 364 41. Asadi S, Wexler AS, Cappa CD, Barreda S, Bouvier NM, Ristenpart WD. Aerosol
365 emission and superemission during human speech increase with voice loudness. *Sci Rep*.
366 2019;9(1):2348. doi:10.1038/s41598-019-38808-z
- 367 42. Patel RB, Skaria SD, Mansour MM, Smaldone GC. Respiratory source control using a
368 surgical mask: An *in vitro* study. *J Occup Environ Hyg*. 2016;13(7):569-576.
369 doi:10.1080/15459624.2015.1043050
- 370 43. Grosskopf KR, Herstein KR. The aerodynamic behavior of respiratory aerosols within
371 a general patient room. 2012;18(4):15.
- 372 44. Chen M-J, Chang K-J, Hsu C-C, Lin P-Y, Liu CJ-L. Precaution and Prevention of
373 Coronavirus Disease 2019 (COVID-19) Infection in the Eye: *J Chin Med Assoc*. Published
374 online April 2020:1. doi:10.1097/JCMA.0000000000000334

- 375 45. Kim J-O, Kim W-S, Kim S-W, et al. Development and Application of Quantitative
376 Detection Method for Viral Hemorrhagic Septicemia Virus (VHSV) Genogroup IVa. *Viruses*.
377 2014;6(5):2204-2213. doi:10.3390/v6052204
- 378 46. Edwards DA, Man JC, Brand P, et al. Inhaling to mitigate exhaled bioaerosols. *Proc*
379 *Natl Acad Sci*. 2004;101(50):17383-17388. doi:10.1073/pnas.0408159101
- 380 47. Holmgren H, Bake B, Olin A-C, Ljungström E. Relation Between Humidity and Size
381 of Exhaled Particles. *J Aerosol Med Pulm Drug Deliv*. 2011;24(5):253-260.
382 doi:10.1089/jamp.2011.0880
- 383 48. Chang T-J, Hsieh Y-F, Kao H-M. Numerical investigation of airflow pattern and
384 particulate matter transport in naturally ventilated multi-room buildings. *Indoor Air*.
385 2006;16(2):136-152. doi:10.1111/j.1600-0668.2005.00410.x

386

387 Figure legends

388 Figure 1: Size distribution of exhaled microdroplets (left) and resulting viral emissions (right)
389 during normal breathing.

390 The left panel shows the average exhaled microdroplet concentration used as input for the
391 simulation, the right panel shows the modelled viral emission per breath for average (red),
392 high and low emitters (spike-lines).

393 Figure 2: Size distribution of exhaled microdroplets (left) and resulting viral emissions (right)
394 during coughing.

395 The left panel shows the average exhaled microdroplet concentration used as input for the
396 simulation, the right panel shows the modelled viral emission per breath for average (red),
397 high and low emitters (spike-lines).



398 Figure 3: Temporal course of airborne virus load in a perfectly mixed room of 50 m³.
399 The simulation estimated the concentration in a closed room for different air exchange
400 rates. The emitter was assumed to have a high virus-load in the lungs and to be coughing
401 intermittently every 30 seconds.



402 Tables

403 Table 1: Plateau concentration for different combinations of air exchange rate, emission form and emitter type.

Air exchange rate (times / hour)	1 / hour	3 / hour	10 / hour	20 / hour
Time until 99% of plateau	169 minutes	77 minutes	26 minutes	14 minutes
Airborne viral concentration at plateau (copies/m ³)				
Regular breathing				
Low emitter	0.00960	0.00431	0.00147	0.00076
Average emitter	9.60	4.31	1.47	0.76
High emitter	47,989	21,550	7,359	3,792
Frequent coughing (every 30 seconds)				
Low emitter	57.25	25.71	8.78	4.52
Average emitter	57,250	25,709	8,779	4,524
High emitter	286,300,000	128,600,000	43,897,000	22,619,000

404





Airborne virus load for high emitter cough
[copies/m³ in PM₁₀]

